1 citations
,
March 2004 in “Journal of the American Academy of Dermatology” ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
January 2007 in “Frontiers in Medicine” Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
5 citations
,
September 2020 in “Proceedings - Baylor University. Medical Center” Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
15 citations
,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
24 citations
,
June 2016 in “Acta dermato-venereologica” Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
March 2026 in “SHILAP Revista de lepidopterología” Rituximab may cause skin issues, but baricitinib can help improve them.
18 citations
,
July 2008 in “Current Oncology Reports” EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
24 citations
,
October 2018 in “JAAD Case Reports” A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
March 2026 in “Lithuanian University of Health Sciences” JAK inhibitors can effectively regrow hair in alopecia areata patients, but ongoing treatment is needed to maintain results.
4 citations
,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
196 citations
,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
Baricitinib may effectively treat oral lichen planus.
1 citations
,
August 2022 in “Journal of Dermatology and Dermatologic Surgery” A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.
1 citations
,
June 2022 in “JAMA” Baricitinib, a medication taken by mouth, was effective in regrowing hair for people with severe hair loss.
2 citations
,
February 2025 in “Archives of Dermatological Research” Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
7 citations
,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
2 citations
,
February 2021 in “Indian Dermatology Online Journal” Imatinib can cause hair loss due to lichen planopilaris.
December 2013 in “Cumhuriyet Tıp Dergisi/Cumhuriyet Üniversitesi Tıp Fakültesi dergisi” Erlotinib can cause acne-like skin issues, needing early treatment and possible dosage adjustments.
4 citations
,
October 2024 in “American Journal of Clinical Dermatology” Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
184 citations
,
February 2015 in “EBioMedicine” A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
1 citations
,
April 2025 in “Experimental Dermatology” Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.
March 2026 in “International Journal of Dermatology and Venereology” Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.
1 citations
,
January 2023 in “Bioscience Journal” Sorafenib and Platycladus orientalis leaf extract together effectively suppress cervical cancer cell growth.